YiChang HEC ChangJiang Pharmaceutical (1558)

Executive Summary

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. More Details

Rewards

Trading at 73% below our estimate of its fair value

Earnings are forecast to grow 5.05% per year

Earnings grew by 22.5% over the past year

Risk Analysis

High level of non-cash earnings

Has a high level of debt

Unstable dividend track record



Snowflake Analysis

Undervalued with adequate balance sheet.

Search for a company to compare.